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THE TRUTH ABOUT SPORTS DRINKS
Industry-university research contracts are damaging
David Packham honorary fellow
Materials Research Centre, University of Bath, Bath BA2 7AY, UK
It is widely recognised that many prominent drug companies
exert a nefarious effect on clinical research through abusing
university sponsorship and confidentiality agreements in
research contracts. Angell’s long editorial experience at theNew
England Journal of Medicine led her to comment “[i]t is simply
no longer possible to believe much of the clinical research . . .
published.”1
Heneghan and colleagues highlight the dubious scientific basis
of manufacturers’ claims that sports drinks enhance
performance.2 One of the companies criticised by
Angell—Glaxo-Smith-Kline—is deeply involved in promoting
sports drinks. The secrecy over industry-university research
contracts described in the study,2 and the readiness of industry
funded academics to attack its conclusions, suggest that similar
abuse may occur in this field.
Most medical journals, including the BMJ, require authors to
publish potential conflicts of interest, but few of the journals
that support the claims of sports drinks manufacturers do.
Despite their putative devotion to the disinterested pursuit of
knowledge, British universities are reluctant to adopt effective
safeguards. The Economics and Social Research Council insists
on the independence and impartiality of its funded research, and
that conflicts of interest are made explicit,3 yet it is far from
clear that universities have adopted such safeguards for other
sources of funding. The University of Bath requires only that
conflicts are discussed with the head of department and not that
they are made explicit in publications. Similarly, “funding
sources and significant collaboration and all commercial,
financial or other ‘interest’ relating to the work” may be kept
secret if “anonymity has been agreed.”4
The serious damage, Angell described, to the integrity of North
American universities after financially rewarding, but
intellectually fraught, industrial research contracts are
undertaken is already occurring in the UK.5
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